171 related articles for article (PubMed ID: 29760982)
1. Biodynamic digital holography of chemoresistance in a pre-clinical trial of canine B-cell lymphoma.
Choi H; Li Z; Sun H; Merrill D; Turek J; Childress M; Nolte D
Biomed Opt Express; 2018 May; 9(5):2214-2228. PubMed ID: 29760982
[TBL] [Abstract][Full Text] [Related]
2. Comparative oncology chemosensitivity assay for personalized medicine using low-coherence digital holography of dynamic light scattering from cancer biopsies.
Hua Z; Li Z; Lim D; Ajrouch A; Karkash A; Jalal S; Childress M; Turek J; Nolte D
Sci Rep; 2024 Feb; 14(1):2760. PubMed ID: 38332203
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
4. Speckle fluctuation spectroscopy of intracellular motion in living tissue using coherence-domain digital holography.
Jeong K; Turek JJ; Nolte DD
J Biomed Opt; 2010; 15(3):030514. PubMed ID: 20614997
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
7. Biodynamic optical assay for embryo viability.
Li Z; Ehmke N; Lorenzo IM; Machaty Z; Nolte D
J Biomed Opt; 2019 Jun; 24(6):1-4. PubMed ID: 31240897
[TBL] [Abstract][Full Text] [Related]
8. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
Shi Y; Zhou P; Han X; He X; Zhou S; Liu P; Yang J; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Zhang S
Chin J Cancer; 2015 Sep; 34(11):522-30. PubMed ID: 26370464
[TBL] [Abstract][Full Text] [Related]
9. Biodynamic imaging for phenotypic profiling of three-dimensional tissue culture.
Sun H; Merrill D; An R; Turek J; Matei D; Nolte DD
J Biomed Opt; 2017 Jan; 22(1):16007. PubMed ID: 28301634
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
12. Intracellular optical doppler phenotypes of chemosensitivity in human epithelial ovarian cancer.
Li Z; An R; Swetzig WM; Kanis M; Nwani N; Turek J; Matei D; Nolte D
Sci Rep; 2020 Oct; 10(1):17354. PubMed ID: 33060663
[TBL] [Abstract][Full Text] [Related]
13. Doppler fluctuation spectroscopy of intracellular dynamics in living tissue.
Li Z; Sun H; Turek J; Jalal S; Childress M; Nolte DD
J Opt Soc Am A Opt Image Sci Vis; 2019 Apr; 36(4):665-677. PubMed ID: 31044988
[TBL] [Abstract][Full Text] [Related]
14. Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy-induced neutropenia in cancer-bearing dogs.
Marcum BA; Li Z; Turek JJ; Moore GE; Nolte DD; Childress MO
Vet Med Sci; 2021 May; 7(3):665-673. PubMed ID: 33369129
[TBL] [Abstract][Full Text] [Related]
15. Common-path interferometer for digital holographic Doppler spectroscopy of living biological tissues.
Jeong K; Lopera MJ; Turek J; Nolte D
J Biomed Opt; 2021 Mar; 26(3):. PubMed ID: 33783149
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of
Custead MR; An R; Turek JJ; Moore GE; Nolte DD; Childress MO
Converg Sci Phys Oncol; 2015; 1(1):. PubMed ID: 27280042
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
18. Biodynamic digital holographic speckle microscopy for oocyte and embryo metabolic evaluation.
Li Z; Lorenzo-Lorenzo IM; An R; Turek J; Nolte DD; Machaty Z
Appl Opt; 2021 Feb; 60(4):A222-A233. PubMed ID: 33690373
[TBL] [Abstract][Full Text] [Related]
19. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
